Current Evaluation of the Clinical Utility of Fluoromethylcholine-( 18 F ) PET / CT in Prostate Cancer

This short review is dedicated to the current statu s of the assessment of a new PET radiopharmaceutica l, fluoromethylcholine-(18F) or FCH, which is taken-up by prostate cancer tissue, in contrary to fluorode xyglucose(18F) or FDG. It seems that FCH could become “the F DG of prostate cancer”, with the same type of achie vements (detection of distant… (More)